Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
暂无分享,去创建一个
J. Silverberg | A. Wollenberg | A. Taieb | E. Baselga | A. Rossi | D. Marcoux | V. Aoki | N. Levit | H. Zhang
[1] M. Boguniewicz,et al. Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis , 2022, Journal of Allergy and Clinical Immunology.
[2] C. Forrest,et al. Sleep disturbance in school-aged children with atopic dermatitis: prevalence and severity in a cross-sectional sample. , 2021, The journal of allergy and clinical immunology. In practice.
[3] J. Canner,et al. Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. , 2021, Journal of the American Academy of Dermatology.
[4] J. Silverberg,et al. Atopic Dermatitis in the Pediatric Population: A Cross-sectional, International, Epidemiologic Study. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[5] H. Simon,et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis , 2020, Allergy.
[6] J. Ring,et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] J. Silverberg,et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study * , 2020, The British journal of dermatology.
[8] B. Poblador-Plou,et al. Prevalence and Comorbidity of Atopic Dermatitis in Children: A Large-Scale Population Study Based on Real-World Data , 2020, Journal of clinical medicine.
[9] Å. Svensson,et al. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review , 2020, Acta dermato-venereologica.
[10] N. Stahl,et al. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension , 2019, The British journal of dermatology.
[11] Kristen M Beck,et al. The impact of pediatric atopic dermatitis on families: A review , 2018, Pediatric dermatology.
[12] A. Muraro,et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] A. Muraro,et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[14] J. Silverberg,et al. Severity strata for five patient‐reported outcomes in adults with atopic dermatitis , 2018, The British journal of dermatology.
[15] P. Boor,et al. Sleep disturbance in children with moderate/severe atopic dermatitis: A case‐control study , 2018, Journal of the American Academy of Dermatology.
[16] J. Silverberg,et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis , 2017, The British journal of dermatology.
[17] J. Ring,et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] Elizabeth Wager,et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3 , 2015, Annals of Internal Medicine.
[19] G. Yancopoulos,et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.
[20] Masutaka Furue,et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.
[21] T. Bieber,et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.
[22] S. Feldman,et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.
[23] J. Gern,et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. , 2011, The Journal of allergy and clinical immunology.
[24] U. Sivaprasad,et al. Th2 Cytokines and Atopic Dermatitis. , 2011, Journal of clinical & cellular immunology.
[25] T Reunala,et al. Patient‐Oriented SCORAD (PO‐SCORAD): a new self‐assessment scale in atopic dermatitis validated in Europe , 2011, Allergy.
[26] J. Silverberg,et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis , 2019, The Journal of allergy and clinical immunology.
[27] J. Silverberg,et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. , 2015, The Journal of investigative dermatology.
[28] J. Ring,et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.
[29] A. Taïeb,et al. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.